Brown Advisory Inc Fate Therapeutics Inc Transaction History

Brown Advisory Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 24, 2024	SELL	$3.54 - $8.35 $92 - $217	-26 Reduced 0.13%	19,338 $141,000
Q3 2023 Oct 24, 2023	BUY	$2.02 - $5.04 $13,604 - $33,944	6,735 Added 53.33%	19,364 $41,000
Q2 2023 Jul 31, 2023	BUY	$4.76 - $6.59 $60,114 - $83,225	12,629 New	12,629 $60,000
Q4 2022 Feb 13, 2023	SELL	$9.86 - $23.83 $5.02 Million - $12.1 Million	-508,942 Reduced 97.89%	10,949 $110,000
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $102,233 - $175,215	4,859 Added 0.94%	519,891 $11.7 Million
Q2 2022 Nov 14, 2022	BUY	$17.78 - $42.39 $206,870 - $493,207	11,635 Added 2.31%	515,032 $12.8 Million
Q2 2022 Aug 02, 2022	BUY	$17.78 - $42.39 $202,194 - $482,059	11,372 Added 2.36%	494,143 $12.2 Million
Q1 2022 Nov 14, 2022	BUY	$29.67 - $60.28 $274,566 - $557,831	9,254 Added 1.87%	503,397 $19.5 Million
Q1 2022 May 09, 2022	BUY	$29.67 - $60.28 $6.42 Million - $13 Million	216,305 Added 81.18%	482,771 $18.7 Million
Q4 2021 Jan 27, 2022	BUY	$47.84 - $64.34 $12.7 Million - $17.1 Million	266,466 New	266,466 $15.6 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $160M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

Stay updated on Brown Advisory Inc with notifications on news.